Literature DB >> 7908406

Inverse agonist activity of beta-adrenergic antagonists.

P Chidiac1, T E Hebert, M Valiquette, M Dennis, M Bouvier.   

Abstract

Agonist-independent properties of the human beta 2-adrenergic receptor (beta 2AR) were studied using the baculovirus expression system in Sf9 cells. In the absence of agonist but in the presence of GTP, membranes from cells expressing the beta 2AR exhibited higher levels of cAMP production than did membranes from uninfected cells or from cells infected with wild-type baculovirus. The increase in cAMP production was proportional to the number of beta 2AR expressed, up to 40 pmol/mg of membrane protein, and it could be inhibited in a dose-dependent manner by beta AR antagonists. The increase and its reversal both were independent of the possible presence of contaminating catecholamines in the culture medium and thus appear to reflect spontaneous beta 2AR activity and direct antagonist-receptor interactions, respectively. The maximal level of inhibition varied among the beta AR ligands tested, to yield the following rank order of "inverse efficacy"; timolol > or = propranolol > alprenolol > or = pindolol > labetalol > dichloroisoproterenol. The same rank order was observed using membranes prepared from Chinese hamster fibroblasts expressing beta 2AR. The effect of timolol was partly blocked by labetalol and dichloroisoproterenol, in an apparently competitive manner. The intracellular cAMP content of Sf9 cells cultured in serum-free medium was also increased by the expression of beta 2AR, and that increase was reversed by timolol and propranolol, consistent with observations in membrane preparations. The properties revealed by the expression of the beta 2AR in Sf9 cells suggest two agonist-independent traits of G protein-linked receptors, i.e., 1) that unliganded receptors are able to activate G proteins both in membrane preparations and in whole cells and 2) that antagonists may mediate their effects not only by preventing the binding of agonists but also by decreasing the propensity of the receptor to assume an active state.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908406

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  78 in total

Review 1.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 2.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

3.  The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects.

Authors:  Kurt A Krobert; Finn Olav Levy
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  Non-competitive antagonism of beta(2)-agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active beta(2)-adrenoceptors.

Authors:  H E Hopkinson; M L Latif; S J Hill
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Development and characterization of pepducins as Gs-biased allosteric agonists.

Authors:  Richard Carr; Yang Du; Julie Quoyer; Reynold A Panettieri; Jay M Janz; Michel Bouvier; Brian K Kobilka; Jeffrey L Benovic
Journal:  J Biol Chem       Date:  2014-11-13       Impact factor: 5.157

6.  G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity.

Authors:  N T Burford; D Wang; W Sadée
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

7.  Protean agonism at histamine H3 receptors in vitro and in vivo.

Authors:  Florence Gbahou; Agnès Rouleau; Séverine Morisset; Régis Parmentier; Sylvain Crochet; Jian-Sheng Lin; Xavier Ligneau; Joël Tardivel-Lacombe; Holger Stark; Walter Schunack; C Robin Ganellin; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

8.  {Beta}-blocker drugs mediate calcium signaling in native central nervous system neurons by {beta}-arrestin-biased agonism.

Authors:  Anastassios V Tzingounis; Mark von Zastrow; Guillermo A Yudowski
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

Review 9.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 10.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.